Serum and tissue vascular endothelial growth factor levels in hydatidiform mole.
Using a specific and sensitive enzyme immunoassay for vascular endothelial growth factor (VEGF), we measured the circulating levels of VEGF in patients with hydatidiform mole as well as in maternal serum during normal pregnancy. VEGF levels in maternal serum were elevated at 7 weeks and then fell to a plateau. Serum VEGF levels were increased in patients with hydatidiform mole above the normal pregnant levels, while no differences were seen related to the development of persistent trophoblastic disease. By semi-quantitative RT-PCR in molar tissue for VEGF and placenta growth factor, a member of VEGF family, neither of the mRNA levels have no relation to the development of persistent trophoblastic disease. These observations suggest serum VEGF levels will be of value as a new circulating marker of hydatidiform mole.
Nomura
S
S
Department of Obstetrics and Gynecology, Nagoya University School of Medicine, Japan. snomura@med.nagoya-u.ac.jp
Okamoto
T
T
Matsuo
K
K
Iwase
K
K
Nakanishi
T
T
Suzuki
H
H
Mizutani
S
S
D016228:Endothelial Growth Factors / Q000378:metabolism*; D005260:Female; D006801:Humans; D006828:Hydatidiform Mole / Q000097:blood*; D007124:Immunoenzyme Techniques; D008222:Lymphokines / Q000378:metabolism*; D011247:Pregnancy; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014594:Uterine Neoplasms / Q000097:blood*; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors